Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. H. Lundbeck A/S
  6. Company
    LUN   DK0010287234

H. LUNDBECK A/S

(LUN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo H. Lundbeck A/S
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as AlzheimerÔÇÖs disease, Bipolar disorder, depression, epilepsy, HuntingtonÔÇÖs disease, ParkinsonÔÇÖs disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of AlzheimerÔÇÖs disease, Azilect for the treatment of ParkinsonÔÇÖs disease, Xenazine for the treatment of HuntingtonÔÇÖs disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Number of employees : 5 628 people.
Sales per Business
2020
Brintellix/Trintellix3 102.0017.6%
Other Pharmaceuticals2 738.0015.5%
Rexulti/Rxulti2 620.0014.8%
Northera2 553.0014.4%
Cipralex/Lexapro2 380.0013.5%
Abilify Maintena2 271.0012.9%
Sabril777.004.4%
Onfi642.003.6%
Other491.002.8%
Vyepti93.000.5%
Exceptional Items5.000%
DKK in Million
Sales per region
20192020Delta
United States8 804.0051.7%9 074.0051.3% +3.07%
International3 892.0022.8%4 057.0023% +4.24%
Europe3 194.0018.7%3 299.0018.7% +3.29%
North America779.004.6%716.004.1% -8.09%
Other660.003.9%491.002.8% -25.61%
Denmark29.000.2%30.000.2% +3.45%
Exceptional Items-322.00-1.9%5.000%-
DKK in Million
Managers
Name Title Age Since
Deborah Dunsire President & Chief Executive Officer 58 2019
Anders G÷tzsche Chief Financial Officer & Executive Vice President 52 2018
Lars Bang Executive VP-Supply Operations & Engineering 59 2011
Johan Luthman EVP & Head-Research & Development 61 2019
Tarek Samad Senior Vice President & Head-Research - 2021
Lars S°ren Rasmussen Chairman 62 2016
Lene Skole-S°rensen Deputy Chairman 62 2015
Lars Erik Holmqvist Independent Director 61 2015
Palle Holm Olesen Vice President-Investor Relations - -
Jacob Tolstrup Executive Vice President-Commercial Operations 49 2017
Members of the board
Name Title Age Since
Lars S°ren Rasmussen Chairman 62 2016
Henrik Sindal Jensen, Dr. Director 51 2004
Lene Skole-S°rensen Deputy Chairman 62 2015
Lars Erik Holmqvist Independent Director 61 2015
Jeremy Max Levin, Dr. Director 66 2017
Jeffrey Berkowitz Director 55 2018
Rikke Kruse Andreasen Director 49 2018
Ludovic Tranholm Otterbein Director 47 -
Dorothea Wenzel, Dr. Director 51 2021
Santiago Arroyo Director 60 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 199,148,222 61,208,525 30.7% 449,896 0.2% 30.7%
Shareholders
NameEquities%
Lundbeck Foundation 137,351,918 69.0%
Invesco Advisers, Inc. 2,035,406 1.02%
The Vanguard Group, Inc. 1,546,935 0.78%
Handelsbanken Fonder AB 1,477,900 0.74%
Polar Capital LLP 1,417,802 0.71%
BlackRock Advisors (UK) Ltd. 962,420 0.48%
Dimensional Fund Advisors LP 916,899 0.46%
Nordea Investment Management AB (Denmark) 724,551 0.36%
Danske Bank A/S (Investment Management) 652,663 0.33%
UBS Asset Management (Americas) Inc. 490,140 0.25%
Holdings
NameEquities%Valuation
H. LUNDBECK A/S (LUN) 449,896 0.23% 14,313,617 USD
IMARA INC. (IMRA) 522,499 2.00% 4,127,742 USD
Company contact information
H. Lundbeck A/S
Ottiliavej 9
Valby, Capital Region 2500

Phone : +45.36.30.13.11
Fax : +45.36.30.19.40
Web : http://www.lundbeck.com/global
Brand Portfolio
In partnership withAllbrands.markets
More brands of H. Lundbeck A/S
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
H. LUNDBECK A/S-7.28%6 145
JOHNSON & JOHNSON9.46%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.19.42%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY46.06%221 348
NOVO NORDISK A/S35.94%212 048
ABBVIE INC.7.75%205 412
MERCK & CO., INC.-6.03%194 639
ASTRAZENECA PLC12.97%178 110
BRISTOL-MYERS SQUIBB COMPANY9.41%150 815
AMGEN INC.5.05%138 778
SANOFI10.23%129 167
GLAXOSMITHKLINE PLC6.38%98 661
ALLERGAN PLC0.97%63 659
CHUGAI PHARMACEUTICAL CO., LTD.-25.71%60 220
BAYER AG4.89%58 607
JIANGSU HENGRUI MEDICINE CO., LTD.-40.52%53 610
TAKEDA PHARMACEUTICAL COMPANY LIMITED-1.94%52 641
DAIICHI SANKYO COMPANY, LIMITED-40.98%37 706
ASTELLAS PHARMA INC.14.74%29 360